Lupin Limited has informed the Exchange regarding a press release dated October 09, 2025, titled "Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has announced a new Strategic Partnership Program aimed at expanding the global reach of its Long-Acting Injectable (LAI) platform. The LAI platform is a specialized drug delivery technology that enables sustained-release injectable medications, typically used in chronic and complex therapy areas. Through this program, Lupin is likely looking to collaborate with other pharmaceutical companies for licensing, co-development, or contract manufacturing of injectable products using its platform. This move signals Lupin's intent to monetize its injectable technology capabilities and broaden its presence in specialty and complex injectable markets. The announcement positions Lupin to tap into growing global demand for long-acting injectable formulations.
Positive for shareholders — opens new revenue opportunities through partnerships and licensing deals, and reinforces Lupin's growth focus on specialty/complex injectables. Likely to be viewed favorably by the market as a strategic growth initiative.